Vivoryon Therapeutics N.V. to Release Half-Year Financial Results
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) is positioned to unveil its half-year financial results for the period ending June 30, 2025. The announcement comes as the company is dedicated to advancing its clinical stage endeavors, particularly regarding innovative treatments for kidney diseases.
Corporate Update Scheduled for September
The report will provide significant insights into the company's operational progress and future directions. Vivoryon plans to share its findings through a live conference call on September 4, 2025. This event offers an exciting opportunity for stakeholders and interested parties to engage with the management and understand the strategic advancements of the company.
Conference Call Details
The public is invited to join the conference call scheduled for 3:00 pm CEST / 9:00 am EDT. Attendees can participate via phone or through a webcast available directly on the company's website. Pre-registration for the phone call is encouraged to ensure smooth access to the call.
About Vivoryon Therapeutics N.V.
Vivoryon Therapeutics is a dynamic biotechnology firm that is at the forefront of developing cutting-edge small molecule medicines aimed at addressing inflammatory and fibrotic disorders, particularly those affecting kidney health. The company remains committed to scientific excellence and innovation in pursuit of better patient outcomes.
One of the flagship projects, varoglutamstat, represents a pioneering treatment option as an orally available QPCT/L inhibitor. This investigational drug is under evaluation specifically for its potential to treat diabetic kidney disease, showcasing Vivoryon's dedication to tackling complex medical challenges.
Public Engagement and Communication
Vivoryon has emphasized the importance of maintaining transparent communication with stakeholders, providing avenues for inquiries and feedback. The investor relations team plays a critical role in disseminating vital information regarding the company's progress. Anyone interested in learning more about Vivoryon's initiatives is encouraged to reach out.
Contact Information
For further details or inquiries, individuals can contact Vivoryon Therapeutics directly via email at IR@vivoryon.com. This communication ensures that investors and stakeholders are well-informed about developments and announcements related to the company's progress.
Frequently Asked Questions
What financial results will Vivoryon Therapeutics report?
Vivoryon Therapeutics will report its half-year financial results for the period ending June 30, 2025.
When is the conference call for the financial results?
The conference call is set for September 4, 2025, at 3:00 pm CEST / 9:00 am EDT.
How can stakeholders participate in the conference call?
Stakeholders can participate via phone or through a live webcast. Pre-registration for the call is encouraged for phone participants.
What is varoglutamstat?
Varoglutamstat is Vivoryon's advanced investigational drug, aimed at treating diabetic kidney disease.
How can investors contact Vivoryon Therapeutics?
Investors can reach Vivoryon Therapeutics by emailing IR@vivoryon.com for any inquiries or additional information.
